Schaefer 2006.

Methods	Design: open‐label RCT Duration: not reported Follow up: 12 months
Participants	Setting: single centre Country: USA Primary kidney transplant recipients: DD or non‐HLA identical LD Number (group 1/group 2): 80 (41/39) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusions: not reported
Interventions	Treatment group 1 SRL: 5mg/d from day 3; target levels 8 to 12 ng/mL Treatment group 2 TAC: 0.15mg/kg/d; target levels 8 to 12 ng/mL Co‐interventions MMF: 2g/d MP/prednisolone ATG: 4 doses
Outcomes	Death (all causes) Graft loss censored for death Acute rejection SCr Infection Biochemical adverse effects Cosmetic/lifestyle adverse effects
Notes	Comparison: TOR‐I versus CNI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients accounted for
Selective reporting (reporting bias)	Low risk	Prespecified outcomes mentioned
Other bias	Unclear risk	Insufficient information to permit judgement